These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 23210819)

  • 1. Autologous cell therapies: challenges in US FDA regulation.
    McAllister TN; Audley D; L'Heureux N
    Regen Med; 2012 Nov; 7(6 Suppl):94-7. PubMed ID: 23210819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous cell therapies: the importance of regulatory oversight.
    Werner M; Mayleben T; Van Bokkelen G
    Regen Med; 2012 Nov; 7(6 Suppl):100-3. PubMed ID: 23210820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA challenges stem-cell clinic.
    Cyranoski D
    Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
    [No Abstract]   [Full Text] [Related]  

  • 5. Current regulatory issues in cell and tissue therapy.
    Burger SR
    Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Human Genome Project in the United States: a perspective on the commercial, ethical, legislative and health care issues.
    Mackler BF; Barach M
    J Int Bioethique; 1991; 2(3):149-57. PubMed ID: 11654898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the FDA in new drug development and availability.
    Murgo AJ
    W V Med J; 1991 Jun; 87(6):250-5. PubMed ID: 1862651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
    Sipp D
    Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA review divisions: performance levels and the impact on drug sponsors.
    Milne CP; Kaitin KI
    Clin Pharmacol Ther; 2012 Mar; 91(3):393-404. PubMed ID: 22336592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it possible for FDA regulatory scientists and industry scientists to work together?
    Woosley RL
    Clin Pharmacol Ther; 2012 Mar; 91(3):390-2. PubMed ID: 22343817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identity and ownership issues in the regulation of autologous cells.
    Sipp D
    Regen Med; 2017 Oct; 12(7):827-838. PubMed ID: 29115180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global harmonization of regulatory requirements for premarket approval of autologous cell therapies.
    Ward SM
    Food Drug Law J; 2000; 55(2):225-43. PubMed ID: 12269366
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA sets safety framework for cell and tissue therapies: rules would cover attempted human cloning.
    Schwartz J
    Washington Post; 1997 Mar; ():A3. PubMed ID: 11647154
    [No Abstract]   [Full Text] [Related]  

  • 15. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hurdles in tissue engineering/regenerative medicine product commercialization: a pilot survey of governmental funding agencies and the financial industry.
    Bertram TA; Tentoff E; Johnson PC; Tawil B; Van Dyke M; Hellman KB
    Tissue Eng Part A; 2012 Nov; 18(21-22):2187-94. PubMed ID: 22838399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Has the FDA Amendments Act of 2007 impaired drug development?
    Franson TR
    Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA faces regulatory challenges with new approaches to medicine.
    Roehr B
    BMJ; 2014 Feb; 348():g1530. PubMed ID: 24531207
    [No Abstract]   [Full Text] [Related]  

  • 19. Regulatory crackdown on stem cell therapy: what would the position be in South Africa?
    Jordaan D
    S Afr Med J; 2012 Mar; 102(4):219-20. PubMed ID: 22464500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New rules for new drugs: the challenge of AIDS to the regulatory process.
    Edgar H; Rothman DJ
    Milbank Q; 1990; 68(Suppl. 1):111-42. PubMed ID: 11650413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.